Investigational drug · Phase 2
TTI-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "TTI-101"
First trial start
2023
Mar 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTI-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Idiopathic pulmonary fibrosis · Oncology · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TTI-101" as an intervention, largest first.
Tvardi Therapeutics, IncorporatedIndustry
NCT05440708 · 193 participants (planned) · Start Mar 23, 2023 · Primary completion May 25, 2027
Drug: TTI-101; Pembrolizumab and 2 more · For: Hepatocellular Carcinoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 21 sites in all
- Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
Tvardi Therapeutics, IncorporatedIndustry
NCT05671835 · 100 participants · Start May 15, 2023 · Primary completion Aug 14, 2025
Drug: TTI-101; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; La Jolla, California; Orange, California · 28 sites in all
Tvardi Therapeutics, IncorporatedIndustry
NCT03195699 · 64 participants · Start Nov 15, 2017 · Primary completion Jun 24, 2024
Drug: TTI-101; TTI-101 · For: Breast Cancer; Head and Neck Squamous Cell Carcinoma; Non Small Cell Lung Cancer and 5 more
Sites: Houston, Texas; San Antonio, Texas
Washington University School of MedicineAcademic, hospital or other
NCT06141031 · 24 participants (planned) · Start Jan 16, 2024 · Primary completion Jun 30, 2029
Drug: TTI-101 · For: Pancreatic Cancer
Sites: Aurora, Colorado; St Louis, Missouri
Tvardi Therapeutics, IncorporatedIndustry
NCT05384119 · 6 participants · Start Jan 9, 2023 · Primary completion May 6, 2024
Drug: TTI-101; Palbociclib and 3 more · For: Breast Cancer
Sites: Fort Lauderdale, Florida; St Louis, Missouri; Nashville, Tennessee · 6 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05668949 · 0 participants · Start Sep 23, 2025 · Primary completion Sep 23, 2025
Drug: TTI-101; Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05845307 · 0 participants · Start Jun 20, 2025 · Primary completion Nov 13, 2025
Drug: Control Group; TTI-101 · For: Squamous Cell Carcinoma of Head and Neck
Newest research
PubMed records naming it or its code names, newest first.
- Colitis-Associated Colorectal Cancer-STAT3 Inhibition as a Preventive Strategy.
Robinson P, Hoang T, Italia Z, et al. · Int J Mol Sci 2026
- Metabolic Reprogramming of NSUN2-Mediated m5C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-Mediated Cytotoxicity.
Mao S, Fang Y, Gao J, et al. · Cancer Commun (Lond) 2026
- Roles of STAT3 and STAT Family Proteins and Their Signaling Pathways in Thyroid Cancer.
Masaki C, Inoue N, Chiba T · Cells 2026
- BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3.
Che L, Stevenson CK, Plas DR, et al. · Cell Death Dis 2025
- STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer.
Robinson P, Italia Z, Italia Z, et al. · Int J Mol Sci 2025
- EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer.
Paiva EG, Orr B, Azeredo A, et al. · Mol Oncol 2025
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.